PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
van Zyl, D.G.* ; Mautner, J. ; Delecluse, H.-J.*

Progress in EBV vaccines.

Front. Oncol. 9:104 (2019)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The Epstein-Barr virus (EBV) is a ubiquitous pathogen that imparts a significant burden of disease on the human population. EBV is the primary cause of infectious mononucleosis and is etiologically linked to the development of numerous malignancies. In recent years, evidence has also been amassed that strongly implicate EBV in the development of several autoimmune diseases, including multiple sclerosis. Prophylactic and therapeutic vaccination has been touted as a possible means of preventing EBV infection and controlling EBV-associated diseases. However, despite several decades of research, no licensed EBV vaccine is available. The majority of EBV vaccination studies over the last two decades have focused on the major envelope protein gp350, culminating in a phase II clinical trial that showed soluble gp350 reduced the incidence of IM, although it was unable to protect against EBV infection. Recently, novel vaccine candidates with increased structural complexity and antigenic content have been developed. The ability of next generation vaccines to safeguard against B-cell and epithelial cell infection, as well as to target infected cells during all phases of infection, is likely to decrease the negative impact of EBV infection on the human population.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.137
1.158
33
44
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Ebv (epstein-barr Virus) ; Lympho Proliferative Disorder ; Oncogenic ; Vaccine ; γ-herpesvirus; Epstein-barr-virus; T-cell Responses; Phase-i Trial; Envelope Glycoprotein Gp340; Ephrin Receptor A2; Infectious-mononucleosis; Cottontop Tamarins; Recombinant Vaccinia; Monoclonal-antibodies; Persistent Infection
Language english
Publication Year 2019
HGF-reported in Year 2019
ISSN (print) / ISBN 2234-943X
e-ISSN 2234-943X
Journal Frontiers in Oncology
Quellenangaben Volume: 9, Issue: , Pages: , Article Number: 104 Supplement: ,
Publisher Frontiers
Publishing Place Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Reviewing status Peer reviewed
Institute(s) Research Unit Gene Vector (AGV)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-501500-001
DOI 10.3389/fonc.2019.00104
WOS ID WOS:000459689300001
Scopus ID 85063295135
PubMed ID 30859093
Erfassungsdatum 2019-03-21
[➜Report correction]